Quantum量子訊息有限公司
← 最新全球產業報告

Extra Corporeal Membrane Oxygenation (ECMO) System Market

研究執行與發布:TechSci Research · 發布日期 2026-05-01 · 180 頁
由量子訊息有限公司(Quantum Information)在台灣代理銷售與提供授權諮詢。

出版商 TechSci Research產業別 Healthcare & Life Sciences出版日期 2026-05-01頁數 180報告編號 TSR-17489

授權報價

Single User License$4,500 USD
Multiple User License$5,500 USD
Custom Research License$8,000 USD
洽詢購買 申請 Sample
完整報告名稱與涵蓋範圍
Extra Corporeal Membrane Oxygenation (ECMO) System Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Modality (Veno-Arterial (VA), Veno-Venous (VV), Others), By Application (Respiratory Applications, Cardiac Applications, Extracorporeal Cardiopulmonary Resuscitation (ECPR)), By End-User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region & Competition, 2021-2031F

報告摘要

Market Overview The Global Extra Corporeal Membrane Oxygenation (ECMO) System Market is projected to expand from USD 575.2 Million in 2025 to USD 809.49 Million by 2031, exhibiting a Compound Annual Growth Rate of 5.86%. ECMO systems are advanced medical devices that offer extended cardiac and respiratory assistance by oxygenating blood outside the body for individuals suffering from severe heart or lung failure. This market growth is primarily driven by the increasing incidence of chronic cardiopulmonary conditions, a burgeoning global elderly population prone to critical organ dysfunction, and the expanding clinical deployment of these systems within adult intensive care units. For instance, the Extracorporeal Life Support Organization (ELSO) reported a total of 245,291 extracorporeal life support procedures globally through 2024, as noted in its April 2025 registry report, highlighting widespread utilization. Despite this growth, the market faces considerable challenges, notably the significant costs associated with acquiring ECMO devices and the complex nature of the therapy itself. Managing this sophisticated equipment and mitigating severe risks, such as bleeding or infection, necessitates a specialized multidisciplinary team, which in turn limits accessibility for smaller healthcare facilities. Therefore, the substantial financial outlay and a critical scarcity of trained professionals pose major impediments to the widespread adoption of this technology across varied healthcare infrastructures. Market Driver Technological progress in device portability and miniaturization is a primary catalyst for the Global ECMO System Market, facilitating quick deployment beyond conventional hospital environments. The development of compact, lightweight systems enables earlier patient intervention and safer transportation, extending life support capabilities to ambulances and smaller medical facilities. This trend is exemplified by Inspira Technologies' FDA 510(k) clearance in May 2024 for its INSPIRA ART100 system, a less invasive blood oxygenation technology. Furthermore, significant research investment, such as the over $18 million awarded to Johns Hopkins Medicine in December 2024 for creating a portable, rapid-deployment ECMO device, is further advancing these capabilities. Simultaneously, the increasing worldwide occurrence of severe cardiopulmonary disorders is a crucial factor sustaining the demand for mechanical circulatory support. As chronic heart failure and respiratory distress become more prevalent, the need for transitional therapies to stabilize patients for recovery or transplantation intensifies. The American Heart Association's January 2024 report on heart disease and stroke statistics underscores this burden, noting over 800,000 annual cardiovascular disease deaths in the U.S., which highlights the profound clinical requirement for advanced interventions like ECMO. This expanding patient demographic motivates healthcare providers to incorporate extracorporeal support into standard critical care protocols for managing highly fatal conditions. Market Challenge The Global ECMO System Market's growth is considerably constrained by substantial financial costs and a severe scarcity of skilled professionals. Extracorporeal life support therapy is complex, requiring not only costly equipment but also a specialized, multidisciplinary team of experts available 24/7. This requirement establishes a significant hurdle for smaller healthcare facilities and developing regions, largely restricting market penetration to major, well-resourced academic medical centers. As a result, the inability to implement these systems universally limits both the potential installed base and the volume of procedures performed. The intricate nature of ECMO therapy mandates diligent management to minimize risks, thereby increasing the demand for highly skilled professionals who are already in short supply. The Extracorporeal Life Support Organization's April 2025 international registry report indicates an overall survival rate of 64% to discharge or transfer for these high-acuity patients, underscoring the high level of proficiency needed. This highlights how the shortage of qualified personnel directly impedes the broader adoption of ECMO technology. Market Trends The swift integration of Extracorporeal Cardiopulmonary Resuscitation (ECPR) is transforming emergency medical practices by offering immediate circulatory support for refractory cardiac arrest. This method extends the critical intervention period when standard resuscitation proves ineffective, leading to its growing implementation in advanced medical facilities. As healthcare institutions standardize their cannulation techniques, the clinical success rates for this demanding procedure are showing a notable improvement. For example, an article in the Annals of Emergency Medicine (January 2025) reported that favorable neurological outcomes for ECPR patients rose to 37% by the end of the study, confirming this positive trend. Concurrently, there is a clear trend towards adopting awake and ambulatory ECMO protocols, which are enhancing care for patients awaiting organ transplants. This innovative approach minimizes the need for sedation and mechanical ventilation, allowing patients to retain physical mobility and prevent muscle wasting before surgery. By prioritizing rehabilitation during extracorporeal support, medical professionals are significantly improving patient stability and viability for post-transplant success. The effectiveness of this strategy is highlighted in the ASAIO Journal (July 2024), where the 90-day waitlist survival rate for ambulatory veno-venous ECMO patients reached 86%, considerably surpassing that of non-ambulatory groups. Key Market Players * Alung Technologies Inc. * Eurosets * Getinge AB * Medtronic PLC * Microport Scientific Corporation * Nipro Medical Corporation * Terumo Medical Corporation * Abbott Laboratories * Fresenius Medical Care Company Report Scope In this report, the Global Extra Corporeal Membrane Oxygenation (ECMO) System Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Extra Corporeal Membrane Oxygenation (ECMO) System Market, By Modality * Veno-Arterial (VA) * Veno-Venous (VV) * Others # Extra Corporeal Membrane Oxygenation (ECMO) System Market, By Application * Respiratory Applications * Cardiac Applications * Extracorporeal Cardiopulmonary Resuscitation (ECPR) # Extra Corporeal Membrane Oxygenation (ECMO) System Market, By End-User * Hospitals & Clinics * Ambulatory Care Centers * Others # Extra Corporeal Membrane Oxygenation (ECMO) System Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Extra Corporeal Membrane Oxygenation (ECMO) System Market. Available Customizations: Global Extra Corporeal Membrane Oxygenation (ECMO) System Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview 1.1. Market Definition 1.2. Scope of the Market 1.2.1. Markets Covered 1.2.2. Years Considered for Study 1.2.3. Key Market Segmentations 2. Research Methodology 2.1. Objective of the Study 2.2. Baseline Methodology 2.3. Key Industry Partners 2.4. Major Association and Secondary Sources 2.5. Forecasting Methodology 2.6. Data Triangulation & Validation 2.7. Assumptions and Limitations 3. Executive Summary 3.1. Overview of the Market 3.2. Overview of Key Market Segmentations 3.3. Overview of Key Market Players 3.4. Overview of Key Regions/Countries 3.5. Overview of Market Drivers, Challenges, Trends 4. Voice of Customer 5. Global Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 5.1. Market Size & Forecast 5.1.1. By Value 5.2. Market Share & Forecast 5.2.1. By Modality (Veno-Arterial (VA), Veno-Venous (VV), Others) 5.2.2. By Application (Respiratory Applications, Cardiac Applications, Extracorporeal Cardiopulmonary Resuscitation (ECPR)) 5.2.3. By End-User (Hospitals & Clinics, Ambulatory Care Centers, Others) 5.2.4. By Region 5.2.5. By Company (2025) 5.3. Market Map 6. North America Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 6.1. Market Size & Forecast 6.1.1. By Value 6.2. Market Share & Forecast 6.2.1. By Modality 6.2.2. By Application 6.2.3. By End-User 6.2.4. By Country 6.3. North America: Country Analysis 6.3.1. United States Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 6.3.1.1. Market Size & Forecast 6.3.1.1.1. By Value 6.3.1.2. Market Share & Forecast 6.3.1.2.1. By Modality 6.3.1.2.2. By Application 6.3.1.2.3. By End-User 6.3.2. Canada Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 6.3.2.1. Market Size & Forecast 6.3.2.1.1. By Value 6.3.2.2. Market Share & Forecast 6.3.2.2.1. By Modality 6.3.2.2.2. By Application 6.3.2.2.3. By End-User 6.3.3. Mexico Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 6.3.3.1. Market Size & Forecast 6.3.3.1.1. By Value 6.3.3.2. Market Share & Forecast 6.3.3.2.1. By Modality 6.3.3.2.2. By Application 6.3.3.2.3. By End-User 7. Europe Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 7.1. Market Size & Forecast 7.1.1. By Value 7.2. Market Share & Forecast 7.2.1. By Modality 7.2.2. By Application 7.2.3. By End-User 7.2.4. By Country 7.3. Europe: Country Analysis 7.3.1. Germany Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 7.3.1.1. Market Size & Forecast 7.3.1.1.1. By Value 7.3.1.2. Market Share & Forecast 7.3.1.2.1. By Modality 7.3.1.2.2. By Application 7.3.1.2.3. By End-User 7.3.2. France Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 7.3.2.1. Market Size & Forecast 7.3.2.1.1. By Value 7.3.2.2. Market Share & Forecast 7.3.2.2.1. By Modality 7.3.2.2.2. By Application 7.3.2.2.3. By End-User 7.3.3. United Kingdom Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 7.3.3.1. Market Size & Forecast 7.3.3.1.1. By Value 7.3.3.2. Market Share & Forecast 7.3.3.2.1. By Modality 7.3.3.2.2. By Application 7.3.3.2.3. By End-User 7.3.4. Italy Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 7.3.4.1. Market Size & Forecast 7.3.4.1.1. By Value 7.3.4.2. Market Share & Forecast 7.3.4.2.1. By Modality 7.3.4.2.2. By Application 7.3.4.2.3. By End-User 7.3.5. Spain Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 7.3.5.1. Market Size & Forecast 7.3.5.1.1. By Value 7.3.5.2. Market Share & Forecast 7.3.5.2.1. By Modality 7.3.5.2.2. By Application 7.3.5.2.3. By End-User 8. Asia Pacific Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 8.1. Market Size & Forecast 8.1.1. By Value 8.2. Market Share & Forecast 8.2.1. By Modality 8.2.2. By Application 8.2.3. By End-User 8.2.4. By Country 8.3. Asia Pacific: Country Analysis 8.3.1. China Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 8.3.1.1. Market Size & Forecast 8.3.1.1.1. By Value 8.3.1.2. Market Share & Forecast 8.3.1.2.1. By Modality 8.3.1.2.2. By Application 8.3.1.2.3. By End-User 8.3.2. India Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 8.3.2.1. Market Size & Forecast 8.3.2.1.1. By Value 8.3.2.2. Market Share & Forecast 8.3.2.2.1. By Modality 8.3.2.2.2. By Application 8.3.2.2.3. By End-User 8.3.3. Japan Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 8.3.3.1. Market Size & Forecast 8.3.3.1.1. By Value 8.3.3.2. Market Share & Forecast 8.3.3.2.1. By Modality 8.3.3.2.2. By Application 8.3.3.2.3. By End-User 8.3.4. South Korea Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 8.3.4.1. Market Size & Forecast 8.3.4.1.1. By Value 8.3.4.2. Market Share & Forecast 8.3.4.2.1. By Modality 8.3.4.2.2. By Application 8.3.4.2.3. By End-User 8.3.5. Australia Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 8.3.5.1. Market Size & Forecast 8.3.5.1.1. By Value 8.3.5.2. Market Share & Forecast 8.3.5.2.1. By Modality 8.3.5.2.2. By Application 8.3.5.2.3. By End-User 9. Middle East & Africa Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 9.1. Market Size & Forecast 9.1.1. By Value 9.2. Market Share & Forecast 9.2.1. By Modality 9.2.2. By Application 9.2.3. By End-User 9.2.4. By Country 9.3. Middle East & Africa: Country Analysis 9.3.1. Saudi Arabia Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 9.3.1.1. Market Size & Forecast 9.3.1.1.1. By Value 9.3.1.2. Market Share & Forecast 9.3.1.2.1. By Modality 9.3.1.2.2. By Application 9.3.1.2.3. By End-User 9.3.2. UAE Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 9.3.2.1. Market Size & Forecast 9.3.2.1.1. By Value 9.3.2.2. Market Share & Forecast 9.3.2.2.1. By Modality 9.3.2.2.2. By Application 9.3.2.2.3. By End-User 9.3.3. South Africa Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 9.3.3.1. Market Size & Forecast 9.3.3.1.1. By Value 9.3.3.2. Market Share & Forecast 9.3.3.2.1. By Modality 9.3.3.2.2. By Application 9.3.3.2.3. By End-User 10. South America Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 10.1. Market Size & Forecast 10.1.1. By Value 10.2. Market Share & Forecast 10.2.1. By Modality 10.2.2. By Application 10.2.3. By End-User 10.2.4. By Country 10.3. South America: Country Analysis 10.3.1. Brazil Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 10.3.1.1. Market Size & Forecast 10.3.1.1.1. By Value 10.3.1.2. Market Share & Forecast 10.3.1.2.1. By Modality 10.3.1.2.2. By Application 10.3.1.2.3. By End-User 10.3.2. Colombia Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 10.3.2.1. Market Size & Forecast 10.3.2.1.1. By Value 10.3.2.2. Market Share & Forecast 10.3.2.2.1. By Modality 10.3.2.2.2. By Application 10.3.2.2.3. By End-User 10.3.3. Argentina Extra Corporeal Membrane Oxygenation (ECMO) System Market Outlook 10.3.3.1. Market Size & Forecast 10.3.3.1.1. By Value 10.3.3.2. Market Share & Forecast 10.3.3.2.1. By Modality 10.3.3.2.2. By Application 10.3.3.2.3. By End-User 11. Market Dynamics 11.1. Drivers 11.2. Challenges 12. Market Trends & Developments 12.1. Merger & Acquisition (If Any) 12.2. Product Launches (If Any) 12.3. Recent Developments 13. Global Extra Corporeal Membrane Oxygenation (ECMO) System Market: SWOT Analysis 14. Porter's Five Forces Analysis 14.1. Competition in the Industry 14.2. Potential of New Entrants 14.3. Power of Suppliers 14.4. Power of Customers 14.5. Threat of Substitute Products 15. Competitive Landscape 15.1. Alung Technologies Inc. 15.1.1. Business Overview 15.1.2. Products & Services 15.1.3. Recent Developments 15.1.4. Key Personnel 15.1.5. SWOT Analysis 15.2. Eurosets 15.3. Getinge AB 15.4. Medtronic PLC 15.5. Microport Scientific Corporation 15.6. Nipro Medical Corporation 15.7. Terumo Medical Corporation 15.8. Abbott Laboratories 15.9. Fresenius Medical Care Company 16. Strategic Recommendations 17. About Us & Disclaimer

提及公司

1 Alung Technologies Inc.2 Eurosets3 Getinge AB4 Medtronic PLC5 Microport Scientific Corporation6 Nipro Medical Corporation7 Terumo Medical Corporation8 Abbott Laboratories9 Fresenius Medical Care Company

同分類最新報告(醫療與生命科學)

常見問題

這份報告可以先索取樣本嗎?

可以。建議購買前先申請樣本,提出申請後約 2 個工作天內提供,您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算?

報告以美元標價,台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本(單人/多人/企業全站)價格不同,量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付?如何付款?

一般 3–7 個工作天交付,實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票,30 天內電匯付款即可。

量子訊息有限公司為 TechSci Research 在台灣的授權代理,提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們